Aravive — Investor Presentation (May 2023)
35 slides from Aravive's investor presentation, May 16, 2023
Slide 1: Developing Transformative Targeted Cancer Therapeutics
¢3 aravive Developing Transformative Targeted Cancer Therapeutics Corporate Presentation May 2023 NASDAQ: ARAV
Slide 2: Forward Looking Statements
Forward Looking Statements ‘This presentation contains forward-looking statements that may discuss Aravive's plans, goals, intentions and expectations as to future trends, events, results of operations, financial condition or other matters. Forward-looking statements generally inclide statements tha
Slide 3: Batiraxcept: Novel Differentiated Late-Stage Clinical Program for Solid Tumors
Batiraxcept: Novel Differentiated Late-Stage Clinical Program for Solid Tumors ¢ GASG6/AXL signaling drives metastasis and drug-resistance. ARAV is the only company targeting GASS. Wealth of preciinical studies demonstrate abilty to combine with common standards of care to allow access to alarge tot
Slide 4: Experienced Management and Board of Directors
Experienced Management and Board of Directors Senior Management RHANGH 1s Charman oft Boars ed taboman thar. Caley m, OABT Scone, PRD. Ry Hor. CPA. Rabr\Gaer. MD. Casa Pein MBA Be ONION FR unm aconon WSIS Uh Novartis Gaye flmennfehmen anoxG > @ tome eseicene
Slide 5: Aravive Pipeline - Late Stage with Phase Data in Mid-2023
Aravive Pipeline - Late Stage with Phase 3 Data in Mid-2023 Opportunity for Expansion into Additional Indications and Drug Combinations Batiraxcept cone SET 2 Clear Cot Rena 1D Adeltonal mature data fom Cancer (3 coher rack Designation for 2." in Pb mis 2023 int stay) 1 nite P32 2023, Pancreat Adeno
Slide 6: GAS6/AXL Pathway and Batiraxcept
¢°9 aravive @ GAS6/AXL Pathway and Batiraxcept
Slide 7: GAS6/AXL Signaling Drives Resistance and Metastasis in Tumors
GAS6/AXL Signaling Drives Resistance and Metastasis in Tumors’ GAS6 is a survival switch in tumor cells but not essential in normal tissues’, which lowers the potential for side effects + GAS6/AXL pathway mediates metastasis + GAS6 and AXL expressed by tumor and tumor-associated stromal cells to pro
Slide 8: GAS6 & AXL Expression Associated with Poor Survival in Many Cancers
GAS6 & AXL Expression Associated with Poor Survival in Many Cancers AXL expressed in 270% of ovarian, pancreatic, breast, kidney, and uterine cancers" “Clinically, the expression of GAS6 and TAM receptors always predicts poorprognosis"” ‘+ Hao et ak 2017. AKL shighy expressed in ovary-derve tumors a
Slide 9: Effective Oncology Treatment Requires Targeting Both Non-metastatic and Metastatic Tumor Cells
Effective Oncology Treatment Requires Targeting Both Non- metastatic and Metastatic Tumor Cells Batiraxcept specifically targets metastatic tumor cells + Batiraxcept demonstrates single agent activity in preclinical models which have homogeneous, metastatic tumor cells ~ Human tumors display epithel
Slide 10: Batiraxcept is a High Affinity Decoy That Mimics AXL Receptor
Batiraxcept is a High Affinity Decoy That Mimics AXL Receptor Improves on shortcomings of other approaches for potent and selective inhibition of the AXLIGAS6 pathway Ani-AXLor ant-GAS6 Antibody Batioxcopt- Decoy AXL Receptor ‘Baiaxcopt mimics AXL to bind and op yar pe pi AE MU AL Limi te J is sen L
Slide 11: Batiraxcept: High Affinity AXL Decoy Protein
Batiraxcept: High Affinity AXL Decoy Protein Inhibits the GAS6/AXL Pathway by Sequestering the GAS6 Ligand Modified AXL-Fe fusion protein engineered Proprietary biomarker assay for stability and very high affinity for GAS6 for serum GAS6 + ~200-fold greater affinity for GAS6 than the native» _Batira
Slide 12: Dosing Strategy Varies by Indication
Dosing Strategy Varies by Indication Batiraxcept exposure correlates with anti-tumor activity + Knockout data and GLP program did not identify DLT + Traditional MTD or DLT approach for identification of Inffal Jocusion S indications with: RP2D not appropriate for batiraxcept due to its = High unmet
Slide 13: ~$3B in Global Revenue Potential in PROC, Renal and Pancreatic
~$3B in Global Revenue Potential in PROC, Renal and Pancreatic* PROC Represents the Most Near-term Opportunity $3B Peak Potential for all 3 Indications Estimated Treatable Patients PDAC + 37.5K (USA) + 46K (EU4/UK) PROC * 10.5K patients (USA) + 139K patients (UK/EU4) ccRCC + 9k (USA) * 9.5 K (EU4/UK
Slide 14: Batiraxcept: Platinum-Resistant Ovarian Cancer (PROC)
¢°9 aravive @ Batiraxcept: Platinum- Resistant Ovarian Cancer (PROC)
Slide 15: Summary of Phase 1a Healthy Volunteer and 1b PROC Studies
Summary of Phase 1a Healthy Volunteer and 1b PROC Studies No observed dose-limiting toxicities up to 20 mg/kg Phase 1a single ascending dose and repeat dose study in healthy volunteers 43 subjects participated; 42 dosed Batiraxcept was well-tolerated across doses of 1-10 mg/kg Batiraxcept; no SAEs N
Slide 16: Batiraxcept + Paclitaxel Clinical Activity Associated with Exposure in P1b PROC
Batiraxcept + Paclitaxel Clinical Activity Associated with Exposure in P1b PROC Modeling Identified RP2D of 15 mg/kg for PROC + Exposure-response relationship identified by unsupervised computer analysis Efficacy Data for Pationts Receiving 10 mg/kg and 15 — Statistically significant relationship be
Slide 17: Time on Treatment and Depth of Response for Batiraxcept + Paclitaxel Patients
Time on Treatment and Depth of Response for Batiraxcept + Paclitaxel Patients (10 and 15 mg/kg groups) 96% were on 3'+ Line of Therapy; Literature Demonstrates 85% of Patients on their 3" Line of Therapy have Progressive Disease by their First CT Scan' FSO HH OGG RRS vw
Slide 18: Batiraxcept + Chemo - Better Response than Chemo Monotherapy
Batiraxcept + Chemo - Better Response than Chemo Monotherapy Phase 1b Results Compared to Literature These Tumors Expected to be Dependent on the GAS6/AXL Pathway Chemotherapy Alone Batiraxcept + Chemotherapy" Patients with ‘on pad <3mo Platinum o FreeInterval == = (rr) .— oo = |_| | ar a ae ae 9 (e
Slide 19: Batiraxcept Phase 3 Registrational Trial Design in PROC
Batiraxcept Phase 3 Registrational Trial Design in PROC (ClinicarTrials.gov NCT04729608) + FDA Feedback: If positive, trial could support full approval in PROC; no further preclinical or clinical studies required for BLA at this time + Endpoint Assessment: PFS per RECIST V1.1; radiological imaging e
Slide 20: Market Research Suggests Batiraxcept Would Fill an Unmet Need (PROC)
Market Research Suggests Batiraxcept Would Fill an Unmet Need and Be Adopted into the Current PROC Treatment Paradigm To see this level of safety with the “The all-comers data is helpful to improved efficacy is impressive ~ know, but the bev-naive data is | certainly would use this product. quite tr
Slide 21: Batiraxcept: Clear Cell Renal Cell Carcinoma (ccRCC)
¢°3 aravive +) Batiraxcept: Clear Cell Renal Cell Carcinoma (ccRCC)
Slide 22: Batiraxcept + Cabozantinib Phase 1b/2 Trial Design in ccRCC
Batiraxcept + Cabozantinib Phase 1b/2 Trial Design in ccRCC (NCT04300140) Population: + Pb: 26 patients + P2: 55 patients (currently enrolling) + Histologically confirmed metastatic ecRCC and progressed on/after a front-line treatment regimen + Excluded patients previously treated with cabozantinib
Slide 23: P1b ccRCC: Safety Consistent with Established Profile for Cabozantinib
P1b ccRCC: Safety Consistent with Established Profile for Cabozantinib 45 mg/kg Pb P: 20 mg/kg Pb Patients Safety (N=16) (N=10) Batiraxcept-Related Deaths C) ° Grade 3 Adverse Events (AEs), 5 (19.2%) 3 (18.8%) 2 (20%) related to Batiraxcept Events: HTN(x2), Events: HTN (x2), Events: Diarrhea, (No Gr
Slide 24: P1b ccRCC: Clinical Activity by Prior VEGF-TKI Status
P1b ccRCC: Clinical Activity by Prior VEGF-TKI Status Designated Fast Track by FDA for patients who have progressed after 1 or 2 prior lines of systemic therapy that include both immuno-oncology (IO)-based and vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI)-based therapies (e
Slide 25: Batiraxcept Phase 3 Registrational Trial Design in ccRCC
Batiraxcept Phase 3 Registrational Trial Design in ccRCC * Designated Fast Track by FDA in Nov2022 for patients who have progressed after 1 or 2 prior lines of systemic therapy that include both immuno-oncology (I0}-based and vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI)-ba
Slide 26: Market Research Suggests Batiraxcept Would Fill an Unmet Need (ccRCC)
Market Research Suggests Batiraxcept Would Fill an Unmet Need and Be Adopted into the Current ccRCC Treatment Paradigm "The upside efficacy would be If this product actually achieves practice-changing in 2L... | this upside efficacy, | would would offer it fo most of the definitely wait to use cabo
Slide 27: Batiraxcept: Pancreatic Adenocarcinoma
¢3 aravive S Batiraxcept: Pancreatic Adenocarcinoma » ©
Slide 28: Phase 1b Design in 1L Pancreatic Adenocarcinoma
Phase 1b Design in 1L Pancreatic Adenocarcinoma (NCT04983407) Patients with advanced or metastatic pancreatic adenocarcinoma eligible to receive gemcitabine + nab- paclitaxel (Abraxane®) as first-line treatment Lead-inPhase Dose Escalation Batiraxcept Endpoints: 18 malig on days 1& 15 alkgbaticaxcep
Slide 29: Safety Profile Consistent with Gemcitabine + nab Paclitaxel or Underlying Disease in P1b PDAC Study
Safety Profile Consistent with Gemcitabine + nab Paclitaxel or Underlying Disease In P1b PDAC Study Batiraxcept-Related Deaths 829%) Grade 3 Adverse Evens (AE) reatedoBatirarcopt : (No Grade or Ao ralsodto Batracep Gis ee oy este ‘AES ti (2 (10%) s Leading to Batiraxcept Treatment Discontinuation Ev
Slide 30: Batiraxcept in PDAC: Ongoing P1b Study - Efficacy
Batiraxcept in PDAC: Ongoing P1b Study (NCT04983407) - Efficacy P longer on study and have higher response rates, suggesting nts with trough Levels >MEC rem: her batiraxcept doses may improve Modeling studies identified MEC of batiraxceptin PDAC at 14.5 mg/L. Consistent with MEC for PROC and ecRCC +
Slide 31: Market Research Suggests Batiraxcept Would Fill an Unmet Need (PDAC)
Market Research Suggests Batiraxcept Would Fill an Unmet Need and Be Adopted into the Current PDAC Treatment Paradigm ” Efficacy in the base case is similar to FOLFIRINOX, | like that it is more tolerable for patients” Ifthe biomarker high population were really 70%, I would serum test and give [the
Slide 32: Anticipated Upcoming Milestones
Anticipated Upcoming Milestones Gils | P3 top-line results Ifpositive, submit BLA Potential FDA approval Safety and preliminary tai cence Rea nanabaE Initiation of P3 Updated P1b/2a data PDAC Updated data fromP1b initiate P2a* dose escalation “Depends cn mate tom Pb FRC sty 2 6
Slide 33: Financial Summary
Financial Summary $35.9 million Cash and Cash Equivalents As of 3/31/23 No Debt Cash Runway Expected to Fund Operations Into 4Q’ 2023 2
Slide 34: Dedicated to Developing Innovative Treatments for Life-Threatening Diseases
Dedicated to Developing Innovative Treatments for Life-Threatening Diseases to Increase Patient Survival Proprietary, differentiated first-in-class candidate inhibiting GAS6/AXL signaling pathway associated with tumor growth, metastasis, drug resistance, and poor survival rates | Batiraxcept has pot
Slide 35: Developing Transformative Targeted Cancer Therapeutics
¢3 aravive Developing Transformative Targeted Cancer Therapeutics Corporate Presentation May 2023, NASDAG: ARAV